Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11186637B2 · kind B2 · utility
7Cited by
82References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2021 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Jan 21, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.